Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contacts | Login 
  Users Online: 201 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2019  |  Volume : 9  |  Issue : 4  |  Page : 123-128

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease

Department of Internal Medicine and Cardiology, University of Toledo Medical Center, Toledo, Ohio, USA

Correspondence Address:
Dr. Abdelmoniem Moustafa
Departments of Internal Medicine and Cardiology, University of Toledo Medical Center, Toledo, Ohio.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ajm.AJM_73_19

Rights and Permissions

Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but comes at the expense of an increased risk of bleeding. There is a growing body of evidence that the omission of aspirin from TT has the same preventive efficacy in terms of major adverse cardiacvascular and cerebrovascular events (MACCE) with significantly lower bleeding events. The combination of antiplatelet agents and direct oral anticoagulants (DOAC) is a matter of ongoing research. However, initial studies showed favorable safety profile of DOAC over vitamin K antagonist in combination with antiplatelet agents.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded368    
    Comments [Add]    
    Cited by others 1    

Recommend this journal